Tirzepatide Half-Life and Pharmacokinetics
A research-focused look at tirzepatide's half-life of approximately 5 days, its 39 amino acid structure, albumin binding and how PK supports weekly dosing in studies.
What is the half-life of tirzepatide?
The elimination half-life of tirzepatide is reported as approximately 5 days, which is around 120 hours, in published pharmacokinetic (PK) literature. This figure appears in the regulatory product information for the approved prescription medicine and in peer-reviewed population PK analyses. It is the characteristic that, in clinical studies, is described as supporting a once-weekly subcutaneous administration schedule.
A half-life is the time taken for the plasma concentration of a compound to fall by half. A value of around 5 days is long for a peptide, because most unmodified peptides are cleared within minutes to hours. The engineered structure of tirzepatide is what extends its persistence in circulation, and that is the focus of the sections below.
The information here is presented for laboratory and educational reference only. Pepology supplies research-grade material for in vitro and laboratory research use, and nothing on this page describes or recommends use in humans or animals.
The molecule behind the number
Tirzepatide is a synthetic peptide made up of 39 amino acids. Its backbone is based on the native sequence of glucose-dependent insulinotropic polypeptide (GIP), modified so that it acts as a dual agonist at both the GIP and GLP-1 receptors. In receptor-binding studies it shows a higher affinity for the GIP receptor.
Two positions in the sequence are substituted with a non-standard amino acid, alpha-aminoisobutyric acid (Aib), which reduces susceptibility to enzymatic cleavage by dipeptidyl peptidase-4. The reported molecular formula is C225H348N48O68 with a monoisotopic mass of roughly 4810 daltons.
The structural feature most relevant to pharmacokinetics is a C20 fatty diacid (eicosanedioic acid) attached to a lysine residue through a linker. This lipid moiety is the primary driver of the extended half-life, as described in the next section.
Why albumin binding extends the half-life
The C20 fatty diacid chain gives tirzepatide a strong affinity for serum albumin, the most abundant protein in plasma. When a circulating molecule binds reversibly to albumin, it is effectively held in a large, slowly cleared reservoir. This reduces the fraction of free compound available for rapid filtration and degradation at any given moment.
This albumin-binding strategy is a well-established medicinal-chemistry approach for prolonging the residence time of peptides. The bound and free forms exist in equilibrium, so the compound is released gradually, which flattens the concentration curve over time. This is the biochemical reason a 39 amino acid peptide can display a half-life measured in days rather than hours.
- Lipidation with a C20 diacid promotes reversible albumin binding
- Albumin binding lowers renal filtration and slows clearance
- Aib substitutions reduce enzymatic breakdown by DPP-4
- The combined effect is a reported half-life of approximately 5 days
Absorption and distribution
In the published PK literature based on subcutaneous administration in clinical studies, tirzepatide is absorbed slowly from the injection site, with maximum plasma concentrations typically reached over a period measured in hours to a day or more. The slow absorption profile contributes to the smooth concentration-time curve seen across a weekly interval.
Distribution is characterised by a relatively small apparent volume, consistent with a molecule that remains largely within the plasma compartment because of its extensive albumin binding. Population analyses have described the data using a two-compartment model with first-order absorption and elimination.
Metabolism and elimination
Tirzepatide is understood to be metabolised by proteolytic cleavage of the peptide backbone, meaning the chain is progressively broken down into smaller peptide fragments and individual amino acids. This is the same general route by which the body handles endogenous peptides and proteins.
The fatty diacid component is thought to undergo processes analogous to fatty-acid handling, including beta-oxidation of the carbon chain. Because clearance proceeds through these widespread catabolic pathways rather than a single organ-specific enzyme, elimination is gradual, which is consistent with the reported multi-day half-life.
How half-life links to a weekly interval in studies
A general pharmacology principle is that a compound reaches an approximate steady state after roughly four to five half-lives of repeated administration at a fixed interval. With a half-life of around 5 days, a weekly schedule means successive amounts overlap, and plasma levels build toward a plateau over several weeks before stabilising.
This is why clinical pharmacology literature describes the half-life of tirzepatide as the property that enabled a once-weekly subcutaneous regimen in trials. It is a description of observed PK behaviour in those studies, not dosing guidance. Nothing here should be read as an instruction on administration, which is outside the scope of research-use material.
For a comparison of PK profiles across related research peptides, see our overviews below.
Semaglutide half-life explained Semaglutide vs tirzepatide explained
Regulatory status in Australia
In Australia, tirzepatide is the active ingredient in an approved prescription medicine and is classified as a Schedule 4 (Prescription Only Medicine) substance under the Poisons Standard. Lawful supply of the approved medicine requires a valid prescription from an authorised prescriber.
Research-grade tirzepatide supplied for laboratory work is a separate matter. Material supplied on a research-use-only basis is intended for in vitro and laboratory research and is not a TGA-approved product for human or animal use. It should be handled by qualified personnel under appropriate laboratory controls. For a fuller discussion of the legal framework, see the linked overview below.
In an anti-doping context, GIP and GLP-1 receptor agonists are not currently listed as prohibited substances by the World Anti-Doping Agency, though researchers should always confirm current listings directly, as these are reviewed periodically.
Frequently asked questions
What is the half-life of tirzepatide?
Published pharmacokinetic literature reports an elimination half-life of approximately 5 days, which is around 120 hours. This value appears in regulatory product information and in peer-reviewed population PK analyses.
How long does tirzepatide stay in your system?
As a general pharmacology principle, a compound is largely cleared after roughly four to five half-lives. With a half-life of about 5 days, that corresponds to a period of several weeks. This is a theoretical PK estimate, not a statement about use in people.
Why is tirzepatide described as once-weekly in studies?
Its half-life of around 5 days produces overlapping plasma concentrations when given at weekly intervals, which supported a once-weekly subcutaneous schedule in clinical studies. This describes observed PK behaviour and is not administration guidance.
What makes tirzepatide's half-life so long for a peptide?
A C20 fatty diacid moiety attached to the peptide promotes reversible binding to serum albumin, slowing clearance. Non-standard Aib amino acids also reduce enzymatic breakdown. Together these extend the half-life to roughly 5 days.
How does tirzepatide's half-life compare to semaglutide?
Both are long-acting peptides engineered for albumin binding and reported with multi-day half-lives in the once-weekly range. Semaglutide is commonly reported at about 7 days and tirzepatide at approximately 5 days. See our dedicated comparison for detail.
How is tirzepatide metabolised and eliminated?
It is understood to be cleared by proteolytic cleavage of the peptide backbone into smaller fragments and amino acids, with the fatty-acid component handled by processes analogous to fatty-acid metabolism. Clearance is gradual, consistent with its reported half-life.
Is tirzepatide approved in Australia?
Tirzepatide is the active ingredient in an approved Schedule 4 prescription medicine in Australia. Research-grade material supplied for laboratory use is research-use-only and is not TGA-approved for human or animal use.
This article is general information for research buyers. All Pepology products are supplied strictly for laboratory research use only and are not for human or animal use. Every batch is independently tested by Novagen Laboratories and verifiable on a public register.